Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Down 93.2% in July

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI – Get Free Report) was the target of a significant decrease in short interest in July. As of July 31st, there was short interest totaling 231,318 shares, a decrease of 93.2% from the July 15th total of 3,421,439 shares. Currently, 20.0% of the company’s stock are sold short. Based on an average daily volume of 665,888 shares, the short-interest ratio is currently 0.3 days.

Calidi Biotherapeutics Stock Up 0.6%

Shares of Calidi Biotherapeutics stock traded up $0.01 during trading on Tuesday, reaching $1.64. The company’s stock had a trading volume of 231,099 shares, compared to its average volume of 230,617. Calidi Biotherapeutics has a 1-year low of $1.48 and a 1-year high of $96.95. The company has a 50-day simple moving average of $2.19 and a two-hundred day simple moving average of $5.46. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.98 million, a price-to-earnings ratio of -0.02 and a beta of 1.33.

Get Calidi Biotherapeutics alerts:

Calidi Biotherapeutics (NYSEAMERICAN:CLDI – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($6.88) EPS for the quarter.

Institutional Trading of Calidi Biotherapeutics

Large investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in Calidi Biotherapeutics during the 4th quarter valued at approximately $25,000. Geode Capital Management LLC raised its holdings in shares of Calidi Biotherapeutics by 41.7% in the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after buying an additional 12,334 shares during the last quarter. Finally, DRW Securities LLC acquired a new stake in shares of Calidi Biotherapeutics during the fourth quarter worth $173,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

(Get Free Report)

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.

See Also

• Five stocks we like better than Calidi Biotherapeutics
• Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
• AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
• NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
• Apple’s Next iPhone Could Test How Much Pricing Power Is Left

Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.